Home > Publications database > Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma. > print

001     127089
005     20240228140906.0
024 7 _ |a 10.1093/annonc/mdv227
|2 doi
024 7 _ |a pmid:25962442
|2 pmid
024 7 _ |a 0923-7534
|2 ISSN
024 7 _ |a 1569-8041
|2 ISSN
024 7 _ |a altmetric:3987212
|2 altmetric
037 _ _ |a DKFZ-2017-03115
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Meissner, J.
|b 0
245 _ _ |a Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.
260 _ _ |a Oxford
|c 2015
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1521705257_16575
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Chemotherapy-associated ovarian damage comprises not only infertility, but also premature menopause. The latter has been reported as a consequence of alkylating chemotherapy for breast cancer or Hodgkin's lymphoma. In this study, we assessed the long-term impact of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens on ovarian function in patients with aggressive non-Hodgkin lymphoma (NHL).Long-term survivors after CHOP or CHOP plus etoposide (CHOEP) treatment within the Mabthera International Trial or the NHL-B1 trial of the German NHL Study Group were requested to respond to a questionnaire and to consent to blood sampling for hormone assessment.A total of 46 of 81 contacted patients with a median age of 32.5 years at the time of enrolment into the aforementioned clinical trials responded to the questionnaire. The median follow-up after completion of treatment was 14 years. Last menstrual bleeding occurred significantly earlier in patients compared with the general population (47 versus 51 years, P < 0.0001). In comparison to the distribution of menopausal symptoms in the general population, the percentage of women with moderate or severe menopausal symptoms was increased. In 23 patients who agreed to participate in laboratory analyses, anti-Muller hormone as a marker of ovarian reserve was decreased when compared with correspondent age groups of the general population.Although most female patients regain fertility after CHOP-like chemotherapy, late ovarian impairment occurs frequently. Therefore, awareness of such delayed side-effects at the time of counselling is of importance.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Vincristine
|0 5J49Q6B70F
|2 NLM Chemicals
650 _ 7 |a Etoposide
|0 6PLQ3CP4P3
|2 NLM Chemicals
650 _ 7 |a Doxorubicin
|0 80168379AG
|2 NLM Chemicals
650 _ 7 |a Anti-Mullerian Hormone
|0 80497-65-0
|2 NLM Chemicals
650 _ 7 |a Cyclophosphamide
|0 8N3DW7272P
|2 NLM Chemicals
650 _ 7 |a Prednisone
|0 VB0R961HZT
|2 NLM Chemicals
700 1 _ |a Tichy, D.
|0 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
|b 1
|u dkfz
700 1 _ |a Katzke, V.
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 2
|u dkfz
700 1 _ |a Kühn, T.
|0 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
|b 3
|u dkfz
700 1 _ |a Dietrich, S.
|b 4
700 1 _ |a Schmitt, T.
|b 5
700 1 _ |a Ziepert, M.
|b 6
700 1 _ |a Kuhnt, E.
|b 7
700 1 _ |a Rixecker, T.
|b 8
700 1 _ |a Zorn, M.
|b 9
700 1 _ |a Witzens-Harig, M.
|b 10
700 1 _ |a Pfreundschuh, M.
|b 11
700 1 _ |a Ho, A. D.
|b 12
773 _ _ |a 10.1093/annonc/mdv227
|g Vol. 26, no. 8, p. 1771 - 1776
|0 PERI:(DE-600)2003498-2
|n 8
|p 1771 - 1776
|t Annals of oncology
|v 26
|y 2015
|x 1569-8041
909 C O |o oai:inrepo02.dkfz.de:127089
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2ef631585610340ff425c9c31fcabd03
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ANN ONCOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ANN ONCOL : 2015
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebserkrankungen
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21